Novartis appears to have broken the curse of the BTK inhibitor class. | Novartis appears to have broken the curse of the BTK ...

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...

Narcan maker Emergent BioSolutions is joining in on International Overdose Awareness Day by re-upping its "Ready to Rescue" ...

CDMO Lonza is strengthening its market leadership with a newly created role that puts seasoned exec Samanta Cimitan, Ph.D., ...

In a deal that will end intellectual property claims in five countries, including one before the International Trade ...

Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new ...

Alar Pharmaceuticals an untitled letter after finding fault with the company’s exhibit booth | The FDA sent Alar Pharmaceuticals an untitled letter after finding fault with the company’s exhibit booth ...

These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...

Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame. | Late August has been ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...